Clinical trials: sponsored by Deciphera Pharmaceuticals, LLC
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
GIST - Gastrointestinal Stromal Tumor
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
- Trial name
- NCT04530981
- Testing
- Ripretinib, Repaglinide
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies.
- Trial name
- INVICTUS (NCT03353753)
- Testing
- DCC-2618
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 129 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (GIST).
- Trial name
- NCT05080621
- Testing
- Ripretinib, binimetinib
- Sponsor
- Deciphera Pharmaceuticals, LLC
GIST - Gastrointestinal Stromal Tumor
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
This is an open-label, single-arm, multicenter expanded access study to provide patients who have locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST) and have received treatment with at least 2 prior…
- Trial name
- NCT04148092
- Testing
- ripretinib
- Sponsor
- Deciphera Pharmaceuticals, LLC
Locally Advanced Tumors, Metastatic Solid Tumors
A Study of DCC-2701 in Participants With Advanced Solid Tumors
The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.
- Conditions
- Locally Advanced Tumors, Metastatic Solid Tumors, Cancers With MET Genomic Alterations, Cancers With TRK Genomic Alterations
- Trial name
- NCT02228811
- Testing
- DCC-2701 tablet
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Chronic Myeloid Leukemia
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Rationale: DCC-2036 is a potent broad spectrum inhibitor of BCR-ABL kinase. Inhibition of BCR-ABL has been validated for effective treatment of chronic myeloid leukemia (CML).
- Trial name
- NCT00827138
- Testing
- DCC-2036
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Deciphera Pharmaceuticals, LLC